Qiagen Acquires Molecular Staging Assets
Qiagen said this week that it has acquired technology assets from Molecular Staging, including the company’s whole-genome amplification and rolling-circle amplification technologies, for $28.5 million.
Under the terms of the agreement, Qiagen purchased the technology assets of MSI, including more than 160 applied or issued patents, for $28.5 million in cash plus potential earn-outs of up to $6.75 million.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.